Types of ligands

spinqualitylabelsall models Human CXCR4 receptor with cyclic peptide ligand (antagonist) CVX15 (PDB code 3oe0) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Under construction! In biochemistry and pharmacology, a ligand is a substance that forms a complex with a biomolecule to serve a biological purpose. Ligands include: Substrates AChE inhibitors and substrates Drug Metabolism by CYP450 Enzymes Malarial Dihydrofolate Reductase as Drug Target In a substrate reduction therapy a small molecule inhibitor (Zavesca™) is used to inhibit the synthesis of the accumulated glucosylceramide. Inhibitors AChE inhibitors and substrates Drug Metabolism by CYP450 Enzymes In a substrate reduction therapy a small molecule inhibitor (Zavesca™) is used to inhibit the synthesis of the accumulated glucosylceramide. Activators Signaling lipids Neurotransmitters A ligand that can bind to and alter the function of the receptor that triggers a physiological response is called a receptor agonist. Endogenous agonists: Hormones Neurotransmitters In general, receptors for small molecule neurotransmitters such as serotonin will have only one endogenous agonist, but often have many different receptor subtypes (e.g. 13 different receptors for serotonin). On the other hand, neuropeptide receptors (e.g. Delta opioid receptor) tend to have fewer subtypes, but may have several different endogenous agonists. This allows for a high degree of complexity in the body's signalling system, with different tissues often showing quite distinct responses to a particular ligand. Examples of agonists: The synthetic analogue (20S,23S)-epoxymethano-1alpha,25-dihydroxyvitamin D(3) (2a) acts as a 1alpha,25(OH)(2)D(3) superagonist of Vitamin D on Vitamin D receptor and exhibits both antiproliferative and prodifferentiating properties in vitro. Agonist inositol hexakisphosphate binding site in Transport inhibitor response 1 (3c6o). Water molecules are shown as red spheres. Structure of human Bile acid receptor ligand-binding domain (deeppink) complex with non-steroidal agonist, nuclear receptor coactivator 1 peptide (cyan) and sulfate ions (PDB entry 3ruu). Ligands that bind to a receptor but fail to activate the physiological response are receptor antagonists. The ligand-binding domain (LBD) participates directly in agonist/competitive antagonist binding, affects activation gating, and is the portion that forms the 'middle' layer. The competitive antagonist ZK200775 is bound to the LBD in the structure of Glutamate receptor (GluA2). The small molecule ZK200775, a phosphonate quinoxalinedione AMPA antagonist, was studied as a treatment for stroke because it had demonstrated neuroprotective efficacy in experimental models of stroke and tolerability in healthy volunteers; however, in a multicenter, double-blind, randomized, placebo-controlled phase II trial, it was found to have significant sedative effects in patients with acute stroke which precludes its further development as a neuroprotective agent.

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky